Genflow Biosciences moves into eye disease with new gene therapy project
Published: 02:22 10 Apr 2025 EDT
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has launched a new programme aimed at developing gene therapies for eye conditions, expanding the focus of its longevity research into ophthalmology.
The London-listed biotech firm said on Thursday it will work on a treatment using its proprietary SIRT6 gene - a version found in people who live significantly longer than average - delivered to the eye using a specially engineered, non-viral system.
The therapy is being developed to treat a range of ocular diseases, including glaucoma and corneal disorders.
As part of the project, Genflow has signed a material transfer agreement with an unnamed ophthalmology company.
The partnership will focus on adapting Genflow’s SIRT6 gene technology for use in eye treatments and designing a delivery method capable of targeting affected tissue with precision.
CEO Dr Eric Leire, said: "We are thrilled to advance our ophthalmology programme. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy.
"More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma."
Genflow is currently the only publicly listed longevity-focused biotech in Europe and is working to translate advances in healthy ageing into potential therapies.
